Extended prophylaxis with semuloparin reduces VTE after hip fracture surgery .
This report has been verified
by one or more authors of the
original publication.
Extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery - the SAVE-HIP3 study
Bone Joint J. 2013 Apr 1;95-B(4):459-66. doi: 10.1302/0301-620X.95B4.30730Exclusive Author Interview
Dr. Fisher discusses extended venous thromboembolism prophylaxis in patients undergoing hip fracture surgery
Following a 7-10 day open label run-in phase which studied the safety and efficacy of prophylaxis with semuloparin, 469 patients were randomized in a 2:1 ratio to a 19-23-day long treatment of either semuloparin or a placebo in a double blind phase. 23 days after the end of treatment, the semuloparin group had a 79% relative risk reduction in the rate of any venous thromboembolism or all-cause death. It also had the same treatment emergent adverse event profile as the placebo with only 2 clinically relevant bleedings, no thrombocytopenia, or liver injuries.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
